Every story in this section, newest first — page 247 of 373.
Venture Global (NYSE:VG) and global energy giant Vitol announced today the execution of a new, binding agreement for the purchase of approximately 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG).
Mobilicom (NASDAQ:MOB) today announced its financial and operating results for the full year ended December 31, 2025, revealing a strengthened balance sheet and significant commercial momentum within the U.S. defense sector.
Abivax (NASDAQ:ABVX) today announced its full-year 2025 financial results and provided a comprehensive corporate update, underscored by a significantly strengthened capital structure and steady clinical progress.
Gilead Sciences (NYSE:GILD) is nearing a definitive agreement to acquire Ouro Medicines, a biotechnology company focused on chronic immune-mediated diseases, for a total consideration of up to $2 billion.
Wing, the drone delivery unit owned by Alphabet (NASDAQ:GOOGL), today announced it will begin delivering packages to homes in the San Francisco Bay Area in the coming months.
HomesToLife (NASDAQ:HTLM) today announced its audited financial results for the fiscal year ended December 31, 2025, reporting a year of record profitability and sustained international expansion.
Victory Capital Holdings (NASDAQ:VCTR) issued a sharp rebuttal today against the Special Committee of Janus Henderson Group (NYSE:JHG), seeking to "set the record straight" regarding its $57.05 per share acquisition proposal.
Knife River Corporation (NYSE:KNF) today announced the acquisition of Donaldson Brothers Ready Mix, a prominent aggregates-based supplier in western Montana.
Kandal M Venture (NASDAQ:FMFC) today reported financial results for the first half of fiscal 2026, covering the six months ended September 30, 2025.
Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) today announced topline results from the Phase 3 VALOR study evaluating their 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405.
Sealed Air (NYSE:SEE) today announced that it has received all required regulatory approvals for its pending acquisition by funds affiliated with Clayton, Dubilier & Rice (CD&R).
Talphera (NASDAQ:TLPH) today reported financial results for the fourth quarter and full year ended December 31, 2025, detailing the fiscal costs of its ongoing transition into a specialized developer of hospital-based therapies.
Envoy Medical (NASDAQ:COCH) today reported its financial and operational results for the fiscal year ended December 31, 2025, marking a year of significant regulatory progress and balance sheet restructuring.
Avalo Therapeutics (NASDAQ:AVTX), a clinical-stage biotechnology company focused on developing interleukin-1β (IL-1β)-targeting therapies for immune-mediated inflammatory diseases, reported its financial results for the full year ended December 31, 2025.
Cabaletta Bio (NASDAQ:CABA) today reported financial results for the fourth quarter and full year ended December 31, 2025, providing a definitive timeline for the regulatory submission of its lead product candidate.
Xilio Therapeutics (NASDAQ:XLO) today reported its financial results for the fourth quarter and full year ended December 31, 2025, detailing a year of disciplined platform validation and pipeline expansion.
Ondas Holdings (NASDAQ:ONDS) today reported a landmark financial performance for the fourth quarter and full year ended December 31, 2025, marking its transition from an early-stage innovator to a high-scale industrial technology leader.
Cheer Holding (NASDAQ:CHR) officially filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, revealing a year of financial consolidation and strategic preparation.
Arbutus Biopharma (NASDAQ:ABUS) today reported a landmark set of financial and clinical results for the fourth quarter and full year ended December 31, 2025.
BioLineRx (NASDAQ:BLRX) today announced its audited financial results for the full year ended December 31, 2025, detailing a period of significant fiscal discipline and pipeline maturation.
Bausch + Lomb (NYSE:BLCO) today unveiled positive topline results from its pivotal 24-month U.S. clinical trial of the ELIOS System, an innovative, implant-free procedure designed to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
Viatris (NASDAQ:VTRS) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR (venlafaxine hydrochloride) sustained-release capsules for the treatment of adults with generalized anxiety disorder (GAD).
Jacobs (NYSE:J) announced today the completion of its acquisition of the remaining equity interest in PA Consulting, a leading innovation and transformation consultancy.
